U.S. Inflammatory Bowel Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Disease Indication (Ulcerative Colitis and Crohns Disease), By Route of Administration (Oral and Injectables), By Drug Class (IL Inhibitors, TNF Inhibitors, Anti-integrin, JAK Inhibitors, Corticosteroids, ASA Drugs, and Others), By Distribution Channel (Hospital Pharmacy and Retail Pharmacy & Other), and Country Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI108774

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 5.5% from 2023 to 2030
Unit	Value (USD Billion)
Segmentation	By Disease Indication Ulcerative Colitis Crohn's Disease
	By Route of Administration Oral Injectables
	By Drug Class IL Inhibitors TNF Inhibitors Anti-integrin JAK Inhibitors Corticosteroids ASA Drugs Others
	By Distribution Channel Hospital Pharmacy Retail Pharmacy & Other